Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

InspireMD (NSPR) EBIAT (2016 - 2025)

InspireMD filings provide 16 years of EBIAT readings, the most recent being -$11.8 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 28.2% to -$11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$48.8 million, a 52.43% decrease, with the full-year FY2025 number at -$48.8 million, down 52.43% from a year prior.
  • EBIAT hit -$11.8 million in Q4 2025 for InspireMD, up from -$12.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$3.2 million in Q1 2021 to a low of -$13.2 million in Q2 2025.
  • Median EBIAT over the past 5 years was -$5.1 million (2023), compared with a mean of -$6.7 million.
  • Biggest five-year swings in EBIAT: plummeted 82.31% in 2021 and later rose 5.02% in 2023.
  • InspireMD's EBIAT stood at -$4.1 million in 2021, then fell by 18.26% to -$4.8 million in 2022, then fell by 11.56% to -$5.4 million in 2023, then tumbled by 69.73% to -$9.2 million in 2024, then decreased by 28.2% to -$11.8 million in 2025.
  • The last three reported values for EBIAT were -$11.8 million (Q4 2025), -$12.7 million (Q3 2025), and -$13.2 million (Q2 2025) per Business Quant data.